

IF@

PATENT APPLICATION

Applicants : Michael W. WATHEN et al
 Title : METHOD OF PREVENTING OR TREATING
 ATHEROSCLEROSIS OR RESTENOSIS
 Serial No. : 10/651 221 Group: 1614
 Confirmation No.: 7644
 Filed : August 28, 2003 Examiner: Spivack
 Atty. Docket No.: Pharmacia Case 01669




Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

FIRST CLASS MAILING CERTIFICATE

Sir:

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR 1.8 as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450, on June 24, 2004.


 Sidney B. Williams, Jr.

SBW/smd

FLYNN, THIEL, BOUTELL	Dale H. Thiel	Reg. No. 24 323
& TANIS, P.C.	David G. Boutell	Reg. No. 25 072
2026 Rambling Road	Ronald J. Tanis	Reg. No. 22 724
Kalamazoo, MI 49008-1631	Terryence F. Chapman	Reg. No. 32 549
Phone: (269) 381-1156	Mark L. Maki	Reg. No. 36 589
Fax: (269) 381-5465	Liane L. Churney	Reg. No. 40 694
	Brian R. Tumm	Reg. No. 36 328
	Steven R. Thiel	Reg. No. 53 685
	Sidney B. Williams, Jr.	Reg. No. 24 949

Correspondence: Statement of Substance of Interview
 dated June 24, 2004
 including enclosures listed thereon

190.05/03



PATENT APPLICATION

IN THE U.S. PATENT AND TRADEMARK OFFICE

June 24, 2004

Applicants: Michael W. WATHEN et al

For: METHOD OF PREVENTING OR TREATING
ATHEROSCLEROSIS OR RESTENOSIS

Serial No.: 10/651 221 Group: 1614

Confirmation No.: 7644

Filed: August 28, 2003 Examiner: Spivack

Atty. Docket No.: Pharmacia Case 01669

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW

Sir:

This statement is in reply to the Interview Summary dated May 24, 2004.

The undersigned agrees with much of the substance of the Examiner's interview summary. However, during the discussion, the undersigned did point out that some of the prior art cited in the application does refer to compounds that have been patented for use in the treatment of atherosclerosis and restenosis. In this regard, U.S. Patent 6 291 437 is particularly relevant. This patent provides evidence that, contrary to the Examiner's position; etiology of atherosclerosis and restenosis is not immature. Therefore, the record does not support the Examiner's suggestion that additional evidence is required to show that the specification complies with the enablement requirement.

Since the response to the Office Action had already been sent prior to receipt of the Interview Summary, this statement is deemed timely.

Respectfully submitted,



Sidney B. Williams, Jr.

SBW/smd

FLYNN, THIEL, BOUTELL	Dale H. Thiel	Reg. No. 24 323
& TANIS, P.C.	David G. Boutell	Reg. No. 25 072
2026 Rambling Road	Ronald J. Tanis	Reg. No. 22 724
Kalamazoo, MI 49008-1631	Terryence F. Chapman	Reg. No. 32 549
Phone: (269) 381-1156	Mark L. Maki	Reg. No. 36 589
Fax: (269) 381-5465	Liane L. Churney	Reg. No. 40 694
	Brian R. Tumm	Reg. No. 36 328
	Steven R. Thiel	Reg. No. 53 685
	Sidney B. Williams, Jr.	Reg. No. 24 949

Encl: Postal Card

110.0703